In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMO & VISX: Number one in Refractive Surgery

Executive Summary

Advanced Medical Optics, a specialist in ophthalmic surgery, has acquired Visx , the largest manufacture of lasers for vision correction surgery, for a combination of cash and stock worth $1.27 billion. Analysts were surprised by the magnitude of the deal, following so soon on the heels of AMO's $450 million purchase of the ophthalmic surgical business of Pfizer in April, which brought it products for the cataract and glaucoma markets. However, this is not simply the merger of two major ophthalmic companies for the purpose of achieving critical mass; the two companies operate in distinct, largely non-overlapping markets, and to all appearances fit together like hand in glove.
Advertisement

Related Content

Abbott buys AMO, Gets Double-Digit Growth Segment
Ophthalmology's Next Frontier
The Farsightedness of Refractec
AMO Puts a New Spin on Ophthalmic Devices
AMO Puts a New Spin on Ophthalmic Devices

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002253

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel